Michael Mulhern has been appointed chief executive officer of AMRI, a portfolio company of The Carlyle Group and GTCR. He succeeds William S. Marth. Mr. Mulhern previously served as chief executive officer of Sterigenics International, a global provider of contract sterilization, gamma technologies and medical isotopes. Mr. Marth will remain with the company in an advisory role.

Stephen H. Wise, managing director and global head of healthcare for Carlyle, said, “Michael is a highly accomplished executive with a 30-year track record of value creation in the healthcare and distribution sectors. His role as a member of AMRI’s board of directors, coupled with his experience leading three private equity-backed companies, will make this a smooth transition.” 

Dean Mihas, managing director and head of healthcare for GTCR, said, “We thank Bill for his years of successful leadership of AMRI. Since joining the board of directors in 2012 and becoming CEO in 2014, Bill has been instrumental in building AMRI into a leading contract research, development and manufacturing organization. We wish him success in his future endeavors.” 

Since 2002, Mr. Mulhern has served as chief executive officer of three companies backed by GTCR: Sterigenics International, Fairmont Food Group, and American Sanitary. He previously held roles at Baxter International and Alliant Foodservice.